Fiche publication
Date publication
novembre 2025
Journal
ESMO open
Auteurs
Membres identifiés du Cancéropôle Est :
Dr LADOIRE Sylvain
Tous les auteurs :
Cherifi F, Cabel L, Bousrih C, Volant E, Dalenc F, Mery B, Auvray Kuentz M, Mailliez A, Ladoire S, Tassin de Nonneville A, Alexandre M, Benistant L, Leheurteur M, Bailleux C, Debled M, Frenel JS, Loirat D, Bastien E, Aussedat Q, Bidard FC, Aho S, Glenet A, Mourato-Ribeiro J, Johnson A, Christy F, Emile G
Lien Pubmed
Résumé
In the phase III KEYNOTE-522 study (NCT03036488), which defined triple-negative breast cancers (TNBCs) as tumours with an estrogen receptor (ER) level ≤1% (ER-null) according to European Society for Medical Oncology (ESMO) and American Society of Clinical Oncology (ASCO) guidelines, the rate of pathological complete response (pCR) was increased by pembrolizumab addition to neoadjuvant chemotherapy. This combination has become the standard of care for stage II or III TNBC. However, updated ASCO guidelines suggest that tumours with low ER levels should be treated as ER-null. In some European countries, tumours with 1%-9% ER expression, called 'ER-low', are considered and treated as ER-null despite a lack of data concerning this population.
Mots clés
early breast, endocrine receptor low, immunotherapy, neoadjuvant, pathological complete response
Référence
ESMO Open. 2025 11 25;10(12):105907
